© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure
aResearch Institute for Internal Medicine, Rikshospitalet, University of Oslo, N-0027 Oslo, Norway
bSection of Clinical Immunology and Infectious Diseases, Rikshospitalet, University of Oslo, N-0027 Oslo, Norway
cDepartment of Cardiology, Rikshospitalet, University of Oslo, Oslo, Norway
dMedical Department, Bærum Hospital, Sandvika, Norway
*Corresponding author. Tel.: +47-23-073-629; fax: +47-23-073-630. Email address: arne.yndestad{at}klinmed.uio.no
Objective: Increasing evidence supports a role for inflammation in chronic heart failure (CHF). However, the source and the mechanism for this immune activation are unknown. To address this issue we investigated the gene expression of cytokines and the surface expression of activity markers in T-cells and monocytes from CHF patients and healthy controls. Methods: Gene expression of cytokines was analysed by real-time RT-PCR and activation markers by flow cytometry in 14 CHF patients and nine healthy controls. Surface expression of activation markers for T-cells and monocytes were analysed by flow cytometry. Results: T-cells from CHF patients showed enhanced gene expression of chemokines, ligands in the tumor necrosis factor superfamily, as well as the inflammatory cytokines interferon-
and interleukin-18 with similar pattern in ischemic (n = 5) and idiopathic cardiomyopathy (n = 9). In contrast, no differences in cytokine gene expression were found comparing monocytes from CHF patients and controls. Moreover, T-cells from CHF patients had enhanced surface expression of the activation markers CD69 and CD25, while there was no upregulation of the monocyte activation marker CD32 in these patients. Conclusion: T-cells may be a part of the inflammatory response during CHF independent of the etiology of the disorder. Intervention preventing unwanted T-cell activation could represent a new target in the treatment of CHF.
KEYWORDS Heart failure; Immunology; Cytokines; Leukocytes; Gene expression
Time for primary review 22 days.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H76 - H85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yndestad, K.-O. Larsen, E. Oie, T. Ueland, C. Smith, B. Halvorsen, I. Sjaastad, O. H. Skjonsberg, T. M. Pedersen, O.-G. Anfinsen, et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension J Appl Physiol, April 1, 2009; 106(4): 1356 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Fildes, S. M. Shaw, N. Yonan, and S. G. Williams The Immune System and Chronic Heart Failure: Is the Heart in Control? J. Am. Coll. Cardiol., March 24, 2009; 53(12): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Sandberg, B. Halvorsen, A. Yndestad, C. Smith, K. Otterdal, F. R. Brosstad, S. S. Froland, P. S. Olofsson, J. K. Damas, L. Gullestad, et al. Inflammatory Interaction Between LIGHT and Proteinase-Activated Receptor-2 in Endothelial Cells: Potential Role in Atherogenesis Circ. Res., January 2, 2009; 104(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Platis, Q Yu, D Moore, E. Khojeini, P Tsau, and D. Larson The effect of daily administration of IL-18 on cardiac structure and function Perfusion, July 1, 2008; 23(4): 237 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Smith, B. Halvorsen, K. Otterdal, T. Waehre, A. Yndestad, B. Fevang, W. J. Sandberg, U. M. Breland, S. S. Froland, E. Oie, et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins Cardiovasc Res, July 1, 2008; 79(1): 195 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Dahl, L. Gullestad, B. Fevang, A. M. Holm, L. Landro, L. E. Vinge, A. E. Fiane, W. J. Sandberg, K. Otterdal, S. S. Froland, et al. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure Eur J Heart Fail, April 1, 2008; 10(4): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orozco, E. Gemmell, M. Bickel, and G.J. Seymour Interleukin 18 and Periodontal Disease Journal of Dental Research, July 1, 2007; 86(7): 586 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yndestad, L. E. Vinge, R. Bjornerheim, T. Ueland, J. E. Wang, S. S. Froland, H. Attramadal, P. Aukrust, and E. Oie Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats Eur J Heart Fail, December 1, 2006; 8(8): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Jankowska, S. von Haehling, A. Czarny, E. Zaczynska, A. Kus, S. D. Anker, W. Banasiak, and P. Ponikowski Activation of the NF-{kappa}B system in peripheral blood leukocytes from patients with chronic heart failure Eur J Heart Fail, October 1, 2005; 7(6): 984 - 990. [Abstract] [Full Text] [PDF]
|
|